Thymic immunomodulatory peptide (thymalfasin / Zadaxin)
A thymus-derived 28-amino-acid peptide that regulates and strengthens immune responses; sold as prescription drug Zadaxin abroad.
| Class / type | Thymic immunomodulatory peptide (thymalfasin / Zadaxin) |
|---|---|
| Category | Healing, Recovery & Immune |
| Status (Jul 2026) | Research use only |
Thymosin Alpha-1 is a naturally occurring 28-amino-acid peptide from the thymus, the gland that trains immune cells. As the drug thymalfasin (Zadaxin), it's approved in more than 35 countries - though not by the US FDA - for hepatitis and as an immune adjunct.
It has an unusually deep clinical record for a 'peptide,' which sets it apart from most research-use compounds.
It acts on dendritic cells through toll-like receptors (TLR2/TLR9), strengthening Th1 pathogen defense while also promoting immune tolerance. In practice it behaves as an immune normalizer - boosting weak responses and helping rein in dysregulated ones.
It's been studied across 30+ trials and thousands of subjects for chronic hepatitis B and C, as a chemotherapy adjunct, for immune restoration, and (more recently) sepsis and COVID-19, with a consistently favorable safety profile at therapeutic doses.
A long clinical track record and strong safety data relative to newer peptides; users and patients cite immune resilience, fewer infections and better recovery.
Approved and used medically in many countries.
Not FDA-approved in the US; benefit varies by indication. As an immunomodulator, caution is warranted in autoimmune conditions.
Injection-site reactions are possible, and US compounded supply raises purity questions.
Approved abroad as Zadaxin/thymalfasin; in the US it's compounded. It was among peptides reportedly moved toward compounding access in 2026, but confirm current status.
Immune resilience / fewer infections and recovery support; valued for its long clinical track record.
NOT FDA-approved in US (approved as Zadaxin in 35+ countries). Reportedly moved toward Category 1 (compounding access) in 2026; formal FDA rule pending. Verify.